Lota S. Zoth
CIK 1278219 · CHIEF SCIENTIFIC OFFICER · last filed 2026-05-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$87.2K
Companies
11
Total Filings
64
Lifetime Open-Market Net
-$84.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INO | Director | 8,726 | $1.10 | $9.6K | -$37.8K | 15 | 2026-05-21 |
| FFIN | Director | 2,142 | $33.65 | $72.1K | $0 | 1 | 2026-05-05 |
| 89bio, Inc. (ETNB) Delisted | Director | — | $14.84 | — | $0 | 7 | 2025-10-30 |
| ENGNW | Director | — | $0.27 | — | $0 | 3 | 2025-06-16 |
| LUMOS PHARMA, INC. (LUMO) Delisted | Director | 0 | $4.34 | $0 | $0 | 6 | 2024-12-13 |
| ZYME | Director | — | $22.88 | — | $0 | 4 | 2022-12-23 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Director | 10,006 | — | — | $0 | 11 | 2020-01-06 |
| Spark Therapeutics, Inc. (ONCE) Delisted | CHIEF SCIENTIFIC OFFICER | 0 | — | — | $0 | 6 | 2019-12-17 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | — | — | — | $0 | 6 | 2017-07-18 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 2 | 2015-05-08 |
| MEDI | SVP, Chief Financial Officer | 178 | $31.04 | $5.5K | -$46.2K | 3 | 2007-06-19 |
Recent Filings · Page 2 of 7
64 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-16 | INO | Exer (M) | +2,166 | $0 | EDGAR |
| 2024-03-25 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2024-02-05 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | INO | Sell (S) | −5,700 | -$3.2K | EDGAR |
| 2023-05-16 | INO | Mixed | +19,000 | $0 | EDGAR |
| 2023-05-12 | LUMOS PHARMA, INC. (LUMO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-13 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-23 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2022-05-18 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-17 | INO | Mixed | +14,400 | -$7.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.